In B cell cancers, it has been identified as a tumor suppressor [83] and, in recent studies, B cell activation, isotype switching, and plasma cell differentiation were restrained by KDM6a activity [84, 85], suggesting different functional roles in different lymphocyte populations. This evidence concerns the gene KDM6A and neoplasm.